IL127384A0 - Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity - Google Patents

Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Info

Publication number
IL127384A0
IL127384A0 IL12738497A IL12738497A IL127384A0 IL 127384 A0 IL127384 A0 IL 127384A0 IL 12738497 A IL12738497 A IL 12738497A IL 12738497 A IL12738497 A IL 12738497A IL 127384 A0 IL127384 A0 IL 127384A0
Authority
IL
Israel
Prior art keywords
malignant tumors
thyroxine
hormonal activity
thyroxine analogues
treating malignant
Prior art date
Application number
IL12738497A
Other languages
English (en)
Original Assignee
Octamber Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,267 external-priority patent/US5736576A/en
Application filed by Octamber Inc filed Critical Octamber Inc
Publication of IL127384A0 publication Critical patent/IL127384A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12738497A 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity IL127384A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/655,267 US5736576A (en) 1996-06-04 1996-06-04 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US08/833,272 US6017958A (en) 1996-06-04 1997-04-03 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
PCT/US1997/009086 WO1997046228A1 (en) 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Publications (1)

Publication Number Publication Date
IL127384A0 true IL127384A0 (en) 1999-10-28

Family

ID=27096941

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12738497A IL127384A0 (en) 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Country Status (15)

Country Link
US (1) US6017958A (zh)
EP (1) EP0954299B1 (zh)
JP (1) JP4188416B2 (zh)
CN (1) CN1154486C (zh)
AT (1) ATE300292T1 (zh)
AU (1) AU730261B2 (zh)
BR (1) BR9710686A (zh)
CA (1) CA2257235C (zh)
DE (1) DE69733834T2 (zh)
DK (1) DK0954299T3 (zh)
ES (1) ES2246514T3 (zh)
IL (1) IL127384A0 (zh)
NZ (1) NZ333356A (zh)
PT (1) PT954299E (zh)
WO (1) WO1997046228A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
JP2002507567A (ja) * 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション 血管形成を阻害するための安息香酸誘導体
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US20050159490A1 (en) * 2001-01-31 2005-07-21 Eugene Morkin Method to treat chronic heart failure and/or elevated cholesterol levels
AUPR500201A0 (en) 2001-05-14 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Recovery of minerals by flotation
US7030111B2 (en) 2002-06-06 2006-04-18 Canbas Co., Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
EP1664340A1 (en) * 2003-08-08 2006-06-07 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤を用いる疾病の治療方法
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662335A1 (en) * 2006-09-05 2008-03-13 Valeria Ossovskaya Methods for designing parp inhibitors and uses thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
US8133859B2 (en) * 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
MX2010008572A (es) * 2008-02-04 2010-11-30 Bipar Sciences Inc Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
KR101841304B1 (ko) 2010-04-28 2018-03-22 오스나트 에슈어-파비안 치료학적 치료를 제공하기 위한 방법, 조성물 및 키트
PT2885005T (pt) * 2012-08-20 2018-01-03 Merck Patent Gmbh Preparação farmacêutica sólida contendo levotiroxina
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
EP3534957A1 (en) 2016-11-02 2019-09-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
WO1993002444A1 (en) * 1991-07-24 1993-02-04 Vladislav Vladimirovich Volkov Tensioning device for keyboard stringed musical instrument
WO1993024442A1 (en) * 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
WO1997046228A1 (en) 1997-12-11
CN1154486C (zh) 2004-06-23
EP0954299B1 (en) 2005-07-27
AU730261B2 (en) 2001-03-01
CA2257235A1 (en) 1997-12-11
NZ333356A (en) 2000-06-23
ES2246514T3 (es) 2006-02-16
PT954299E (pt) 2005-11-30
CA2257235C (en) 2007-01-30
DE69733834T2 (de) 2006-06-01
BR9710686A (pt) 2000-01-11
EP0954299A4 (en) 2000-09-06
CN1226826A (zh) 1999-08-25
JP2001501590A (ja) 2001-02-06
ATE300292T1 (de) 2005-08-15
JP4188416B2 (ja) 2008-11-26
AU3218297A (en) 1998-01-05
DE69733834D1 (de) 2005-09-01
US6017958A (en) 2000-01-25
EP0954299A1 (en) 1999-11-10
DK0954299T3 (da) 2005-10-31

Similar Documents

Publication Publication Date Title
IL127384A0 (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU1195499A (en) Thyroxine analogues having no significant hormonal activity to treat malignant tumors
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CA2276606A1 (en) Method of treating prostatic diseases using active vitamin d analogues
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
CA2290520A1 (en) Inhibition of p38 kinase activity by aryl ureas
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
NO960445D0 (no) Hudplaster og fremgangsmåter for å administrere testosteron
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
AU6178198A (en) Method of treating a tumor
PT100111A (pt) Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.
MX9700398A (es) Solucion para la modificacion de tumores cancerosos.
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas